REPROCELL News

Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF). 

Continue reading →

Research and Development, Regenerative Medicine, Human Neurons, Disease Model, iPSC


New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products

Continue reading →

Stem Cell Therapy, iPSC, Neurons


  • Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
  • Representative: Chikafumi Yokoyama, PhD
  • Contact: info-us@reprocell.com

“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.

Continue reading →

Hepatocytes, iPSC


  • Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
  • Representative: Chikafumi Yokoyama, PhD
  • Contact: info-us@reprocell.com

Joint Announcement with Ajinomoto Co., Inc.

Continue reading →

iPSC


  • Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
  • Representative: Chikafumi Yokoyama, PhD
  • Contact: info-us@reprocell.com

We are pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.

Continue reading →

iPSC


Announcement: REPROCELL’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income

  • Company: REPROCELL, Inc.
  • Representative: President and Representative Director Shuji Yokoyama (Company code: 4978)
  • Point of contact: Business Management Director Daigo Obita (Telephone: 045-475-3887)

We would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).

Continue reading →

iPSC, Cardiomyocytes